Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 10/20 | 0.63 |
| ▸ | JAK1 | P23458 | 1/20 | 0.54 |
| ▸ | TYK2 | P29597 | 1/20 | 0.54 |
| ▸ | JAK3 | P52333 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.49 |
| ▸ | CDK1 | P06493 | 1/20 | 0.49 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.49 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.49 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6102797 | 0.84 | ADORA2A (0.61) | JAK2JAK1TYK2JAK3CCNB2 | |
| SCHEMBL1250439 | 0.84 | JAK2 (0.79) | JAK2JAK1TYK2JAK3CCNB2 | |
| SCHEMBL1249732 | 0.83 | JAK2 (0.70) | JAK2JAK1TYK2JAK3CCNB2 | |
| SCHEMBL1167941 | 0.83 | BACE1 (0.58) | JAK2 | |
| SCHEMBL1167552 | 0.82 | BACE1 (0.57) | JAK2 | |
| SCHEMBL12781067 | 0.81 | FLT3 (0.62) | JAK2 | |
| SCHEMBL1168505 | 0.79 | JAK2 (0.59) | JAK2MEN1KMT2AMAPTL3MBTL1 | |
| SCHEMBL24340474 | 0.78 | JAK2 (0.84) | JAK2JAK1TYK2MEN1KMT2A | |
| SCHEMBL1167781 | 0.78 | KMT2A (0.56) | JAK2JAK1TYK2JAK3KMT2A | |
| SCHEMBL24339589 | 0.78 | JAK2 (1.00) | JAK2JAK1TYK2JAK3CCNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040186159-A1 | Inhibitors of glycogen synthase kinase-3 (gsk-3) for treating glaucoma | NOVARTIS AG (CH) | 2004-09-23 | — | — | US | claimed |
| EP-2281560-A1 | Inhibitors of glycogen synthase kinase-3 (GSK-3) for treating glaucomatous optic neuropathy | Alcon, Inc. (CH) | 2011-02-09 | — | — | EP | disclosed |
| US-7598288-B2 | Inhibitors of glycogen synthase kinase-3 (GSK-3) for treating glaucoma | ALCON, INC. (CH) | 2009-10-06 | — | — | US | disclosed |
| US-20040186159-A1 | Inhibitors of glycogen synthase kinase-3 (gsk-3) for treating glaucoma | NOVARTIS AG (CH) | 2004-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186159-A1 | Inhibitors of glycogen synthase kinase-3 (gsk-3) for treating glaucoma | GSK3B, GSK3A, GSKIP | JAK2 2797/4885JAK1 3044/4885TYK2 2654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.